Clinical trial
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
NCT02663518 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
- Lead sponsor
- Pfizer
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 28, 2016
- Completion date
- November 23, 2022
- Enrollment
- 249 (actual)
- Sites
- 51
Conditions
As the registry lists them; a condition with its own page is linked.
hematologic malignancies, solid tumor